Earnings Schedules, Acquisition Agreements, and Financial Results Release - Analyst Notes on Mallinckrodt, BioMarin, Salix Pharmaceuticals, St. Jude Medical and Quest Diagnostics

NEW YORK, April 25, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Mallinckrodt plc (NYSE: MNK), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), St. Jude Medical Inc. (NYSE: STJ) and Quest Diagnostics Inc. (NYSE: DGX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1601-100free.

--
Mallinckrodt plc Analyst Notes
On April 21, 2014, Mallinckrodt plc (Mallinckrodt) announced that it has scheduled to release its Q2 FY 2014 financial results on May 8, 2014. A conference call for investors will be held on the same day from 7:30 a.m. to 8:00 a.m. ET, which will be followed by a separate "live" fireside chat question and answer session for investors at the St. Regis New York, 2 East 55th Street at 5th Avenue in New York City. The Company informed that the call can be accessed via its website, while an audio replay of the call will be available by 4:00 p.m. ET same day through 11:59 p.m. ET on May 15, 2014. The full analyst notes on Mallinckrodt are available to download free of charge at:

http://www.analystsreview.com/1601-MNK-25Apr2014.pdf

--
BioMarin Pharmaceutical Inc. Analyst Notes
On April 16, 2014, BioMarin Pharmaceutical Inc. (BioMarin) announced that its CEO, Jean-Jacques Bienaimé, will host a conference call on May 1, 2014, at 5:00 p.m. ET, to discuss the Company's Q1 2014 financial results and provide a general business update. The Company informed that the conference call will be made accessible at its website, and a replay of the call will be archived for a week after the call, which will also be accessible through its website. The full analyst notes on BioMarin are available to download free of charge at:

http://www.analystsreview.com/1601-BMRN-25Apr2014.pdf

--
Salix Pharmaceuticals Ltd. Analyst Notes
On April 22, 2014, Salix Pharmaceuticals Ltd. (Salix), together with Progenics Pharmaceuticals, announced that the submission to the European Medicines Agency (EMA) of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain has been accepted for review. According to the Company, the submission, when approved will add to the current marketing authorization in the European Union (EU), which allows for the use of RELISTOR® in advanced illness patients. Salix also stated that with the approval, it anticipates RELISTOR to become immediately available to this newly expanded population of patients in the EU using opioids to control chronic pain. The full analyst notes on Salix Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/1601-SLXP-25Apr2014.pdf

--
St. Jude Medical Inc. Analyst Notes
On April 16, 2014, St. Jude Medical Inc. (St. Jude Medical) reported its Q1 FY 2014 financial results (period ended March 29, 2014). Net sales for the quarter were up by 1.9% YoY to $1.4 billion. Q1 FY 2014 net earnings attributable to the Company stood at $249 million or $0.86 per diluted share, compared to $223 million or $0.78 per diluted share in Q1 FY 2013. Commenting on the results, Chairman, President and CEO, Daniel J. Starks, stated, "St. Jude Medical delivered a solid first quarter by meeting or exceeding our expectations in each of our technology platforms. These results reinforce our confidence that we are on track to accelerate sales growth as our product mix shifts to faster growing markets and as we continue to launch new products that improve patient outcomes, ensure the highest quality and lower the costs of treating expensive epidemic diseases." The full analyst notes on St. Jude Medical are available to download free of charge at:

http://www.analystsreview.com/1601-STJ-25Apr2014.pdf

--
Quest Diagnostics Inc. Analyst Notes
On April 21, 2014, Quest Diagnostics Inc. (Quest Diagnostics) announced that it has completed the acquisition of Summit Health. According to the Company, the combined business will be referred to as Quest Diagnostics Health and Wellness Services. Commenting on the acquisition, Quest Diagnostics President and CEO Steve Rusckowski said, "Summit solidifies our leadership position in the fast-growing wellness business. This acquisition is well aligned with our strategy to restore growth because it will extend the range of solutions we can offer in the growing health and wellness market." The financial terms of the deal were not disclosed. The full analyst notes on Quest Diagnostics are available to download free of charge at:

http://www.analystsreview.com/1601-DGX-25Apr2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED